{"nctId":"NCT01400776","briefTitle":"Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women","startDateStruct":{"date":"2011-06-29","type":"ACTUAL"},"conditions":["Postmenopausal Vulvovaginal Atrophy"],"count":722,"armGroups":[{"label":"WC3011 Estradiol Vaginal Cream (2 Times/Week)","type":"EXPERIMENTAL","interventionNames":["Drug: WC3011 Estradiol Vaginal Cream"]},{"label":"Vehicle (2 Times/Week)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle"]},{"label":"WC3011 Estradiol Vaginal Cream (3 Times/Week)","type":"EXPERIMENTAL","interventionNames":["Drug: WC3011 Estradiol Vaginal Cream"]},{"label":"Vehicle (3 Times/Week)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle"]}],"interventions":[{"name":"WC3011 Estradiol Vaginal Cream","otherNames":[]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Postmenopausal females ≥35 years with either or both ovaries removed or naturally menopausal with moderate to severe vaginal dryness\n\nExclusion Criteria:\n\n* Hypersensitivity to estrogen and/or progestin therapy\n* Known or suspected premalignant or malignant disease (except successfully treated skin cancers)\n* Manifestation of or treatment for significant cardiovascular disease, congestive heart failure, stroke or ischemic attacks\n* Insulin-dependent diabetes mellitus\n* Increased frequency or severity of headaches while on hormone or estrogen therapy\n* Drug or alcohol addiction within last 2 years\n* Participation in a clinical trial within 30 days\n* Smoking ≥ 15 cigarettes daily\n* Uncontrolled hypertension - systolic blood pressure (BP) ≥ 160 mmHg or diastolic BP ≥ 95 mmHg","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"35 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Participant's Self-Assessment of Severity of Vaginal Dryness to Week 12/Final Visit","description":"The severity of vaginal dryness was assessed and recorded on a questionnaire by the participants using the following 4 point scale where, 0=None (The symptom is not present), 1=Mild (The symptom is present but may be intermittent; does not interfere with participants activities or lifestyle), 2=Moderate (The symptom is present. Participant is usually aware of the symptom, but activities and lifestyle are only occasionally affected), and 3=Severe (The symptom is present. Participant is usually aware and bothered by the symptom and have modified participant's activities and/or lifestyle due to the symptom. The negative change from Baseline indicates improvement. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":"0.50"},{"groupId":"OG001","value":"2.46","spread":"0.52"},{"groupId":"OG002","value":"2.50","spread":"0.50"},{"groupId":"OG003","value":"2.50","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.27","spread":"0.90"},{"groupId":"OG001","value":"-0.99","spread":"0.89"},{"groupId":"OG002","value":"-1.31","spread":"0.93"},{"groupId":"OG003","value":"-1.17","spread":"0.97"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Vaginal pH to Week 12/Final Visit","description":"Vaginal pH was obtained at final visit of the study. The pH was a numeric value from a scale of 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.51","spread":"0.96"},{"groupId":"OG001","value":"6.49","spread":"0.86"},{"groupId":"OG002","value":"6.40","spread":"0.93"},{"groupId":"OG003","value":"6.40","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"1.14"},{"groupId":"OG001","value":"-0.37","spread":"0.92"},{"groupId":"OG002","value":"-0.99","spread":"1.05"},{"groupId":"OG003","value":"-0.46","spread":"0.90"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Percentage of Vaginal Superficial Cells to Week 12/Final Visit","description":"Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"3.76"},{"groupId":"OG001","value":"0.66","spread":"1.62"},{"groupId":"OG002","value":"0.79","spread":"1.63"},{"groupId":"OG003","value":"0.66","spread":"1.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.44","spread":"14.74"},{"groupId":"OG001","value":"3.05","spread":"7.11"},{"groupId":"OG002","value":"17.30","spread":"19.27"},{"groupId":"OG003","value":"4.02","spread":"12.16"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Percentage of Vaginal Parabasal Cells to Week 12/Final Visit","description":"Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.36","spread":"43.46"},{"groupId":"OG001","value":"47.78","spread":"44.51"},{"groupId":"OG002","value":"42.56","spread":"41.03"},{"groupId":"OG003","value":"45.24","spread":"42.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":"42.76"},{"groupId":"OG001","value":"-8.20","spread":"29.56"},{"groupId":"OG002","value":"-38.5","spread":"39.78"},{"groupId":"OG003","value":"-16.0","spread":"32.75"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Investigator's Assessment of Atrophy to Week 12 and Week 12/Final Visit","description":"Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to atrophy scored on a 4-point scale where: 0= none, 1= mild, 2= moderate, or 3= severe. The negative change from Baseline indicates improvement. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":"0.60"},{"groupId":"OG001","value":"1.94","spread":"0.70"},{"groupId":"OG002","value":"1.90","spread":"0.64"},{"groupId":"OG003","value":"1.88","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.77","spread":"0.80"},{"groupId":"OG001","value":"-0.47","spread":"0.71"},{"groupId":"OG002","value":"-0.76","spread":"0.81"},{"groupId":"OG003","value":"-0.44","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"0.80"},{"groupId":"OG001","value":"-0.48","spread":"0.72"},{"groupId":"OG002","value":"-0.75","spread":"0.81"},{"groupId":"OG003","value":"-0.44","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Investigator's Assessment of Pallor to Week 12 and Week 12/Final Visit","description":"Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to pallor scored on a 4-point scale where: 0= none, 1= mild, 2= moderate, or 3= severe. The negative change from Baseline indicates improvement. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"0.67"},{"groupId":"OG001","value":"1.72","spread":"0.76"},{"groupId":"OG002","value":"1.74","spread":"0.70"},{"groupId":"OG003","value":"1.83","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":"0.81"},{"groupId":"OG001","value":"-0.36","spread":"0.75"},{"groupId":"OG002","value":"-0.78","spread":"0.79"},{"groupId":"OG003","value":"-0.59","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.71","spread":"0.82"},{"groupId":"OG001","value":"-0.39","spread":"0.76"},{"groupId":"OG002","value":"-0.77","spread":"0.80"},{"groupId":"OG003","value":"-0.59","spread":"0.81"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Investigator's Assessment of Vaginal Dryness to Week 12 and Week 12/Final Visit","description":"Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to vaginal dryness scored on a 4-point scale where: 0= none, 1= mild, 2= moderate, or 3= severe. The negative change from Baseline indicates improvement. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":"0.68"},{"groupId":"OG001","value":"1.85","spread":"0.73"},{"groupId":"OG002","value":"1.83","spread":"0.75"},{"groupId":"OG003","value":"1.87","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.94","spread":"0.88"},{"groupId":"OG001","value":"-0.53","spread":"0.82"},{"groupId":"OG002","value":"-0.90","spread":"0.89"},{"groupId":"OG003","value":"-0.74","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.91","spread":"0.89"},{"groupId":"OG001","value":"-0.55","spread":"0.83"},{"groupId":"OG002","value":"-0.89","spread":"0.90"},{"groupId":"OG003","value":"-0.76","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Investigator's Assessment of Friability to Week 12 and Week 12/Final Visit","description":"Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to friability scored on a 4-point scale where: 0= none, 1= mild, 2= moderate, or 3= severe. The negative change from Baseline indicates improvement. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"0.91"},{"groupId":"OG001","value":"1.02","spread":"0.94"},{"groupId":"OG002","value":"0.94","spread":"0.89"},{"groupId":"OG003","value":"1.04","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"0.90"},{"groupId":"OG001","value":"-0.47","spread":"0.86"},{"groupId":"OG002","value":"-0.60","spread":"0.87"},{"groupId":"OG003","value":"-0.52","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"0.89"},{"groupId":"OG001","value":"-0.48","spread":"0.86"},{"groupId":"OG002","value":"-0.61","spread":"0.86"},{"groupId":"OG003","value":"-0.52","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Investigator's Assessment of Petechiae to Week 12 and Week 12/Final Visit","description":"Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to petechiae scored on a 4-point scale where: 0= none, 1= mild, 2= moderate, or 3= severe. The negative change from Baseline indicates improvement. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":"0.78"},{"groupId":"OG001","value":"0.89","spread":"0.89"},{"groupId":"OG002","value":"0.70","spread":"0.83"},{"groupId":"OG003","value":"0.71","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.74"},{"groupId":"OG001","value":"-0.38","spread":"0.72"},{"groupId":"OG002","value":"-0.47","spread":"0.82"},{"groupId":"OG003","value":"-0.29","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"0.73"},{"groupId":"OG001","value":"-0.40","spread":"0.71"},{"groupId":"OG002","value":"-0.46","spread":"0.82"},{"groupId":"OG003","value":"-0.30","spread":"0.75"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Participant's Self-Assessment of Severity of Vaginal Dryness to Weeks 2, 4, 8 and 12","description":"Participant's self-assessment of symptoms of VVA (severity of vaginal dryness) was scored according to a 4-point scale where: 0= none, 1= mild, 2= moderate, or 3= severe. The negative change from Baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":"0.50"},{"groupId":"OG001","value":"2.46","spread":"0.52"},{"groupId":"OG002","value":"2.50","spread":"0.50"},{"groupId":"OG003","value":"2.50","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"0.86"},{"groupId":"OG001","value":"-0.79","spread":"0.88"},{"groupId":"OG002","value":"-0.95","spread":"0.90"},{"groupId":"OG003","value":"-0.79","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.07","spread":"0.82"},{"groupId":"OG001","value":"-0.93","spread":"0.90"},{"groupId":"OG002","value":"-1.12","spread":"0.91"},{"groupId":"OG003","value":"-0.95","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.25","spread":"0.84"},{"groupId":"OG001","value":"-1.02","spread":"0.90"},{"groupId":"OG002","value":"-1.43","spread":"0.90"},{"groupId":"OG003","value":"-1.11","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.30","spread":"0.91"},{"groupId":"OG001","value":"-0.97","spread":"0.90"},{"groupId":"OG002","value":"-1.36","spread":"0.94"},{"groupId":"OG003","value":"-1.20","spread":"0.98"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Participant's Self-Assessment of Vaginal and/or Vulvar Irritation/Itching to Weeks 2, 4, 8, 12 and Week 12/Final Visit","description":"Participant's self-assessment of symptoms of VVA (vaginal and/or vulvar irritation/itching) was scored according to a 4-point scale where: 0= none, 1= mild, 2= moderate, or 3= severe. The negative change from Baseline indicates improvement. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"0.96"},{"groupId":"OG001","value":"1.33","spread":"1.00"},{"groupId":"OG002","value":"1.11","spread":"0.96"},{"groupId":"OG003","value":"1.20","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"1.09"},{"groupId":"OG001","value":"-0.67","spread":"0.95"},{"groupId":"OG002","value":"-0.48","spread":"1.05"},{"groupId":"OG003","value":"-0.48","spread":"1.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.62","spread":"1.14"},{"groupId":"OG001","value":"-0.71","spread":"0.92"},{"groupId":"OG002","value":"-0.48","spread":"1.08"},{"groupId":"OG003","value":"-0.65","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.71","spread":"1.11"},{"groupId":"OG001","value":"-0.82","spread":"1.03"},{"groupId":"OG002","value":"-0.57","spread":"0.97"},{"groupId":"OG003","value":"-0.58","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.75","spread":"1.03"},{"groupId":"OG001","value":"-0.74","spread":"1.02"},{"groupId":"OG002","value":"-0.59","spread":"1.04"},{"groupId":"OG003","value":"-0.70","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"1.01"},{"groupId":"OG001","value":"-0.74","spread":"1.03"},{"groupId":"OG002","value":"-0.58","spread":"1.02"},{"groupId":"OG003","value":"-0.63","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Participant's Self-Assessment of Dysuria (Painful or Difficult Urination) to Weeks 2, 4, 8, 12 and Week 12/Final Visit","description":"Participant's self-assessment of symptoms of VVA (dysuria) was scored according to a 4-point scale where: 0= none, 1= mild, 2= moderate, or 3= severe. The negative change from Baseline indicates improvement. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"0.70"},{"groupId":"OG001","value":"0.49","spread":"0.75"},{"groupId":"OG002","value":"0.45","spread":"0.75"},{"groupId":"OG003","value":"0.53","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.67"},{"groupId":"OG001","value":"-0.22","spread":"0.71"},{"groupId":"OG002","value":"-0.28","spread":"0.74"},{"groupId":"OG003","value":"-0.38","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.68"},{"groupId":"OG001","value":"-0.30","spread":"0.60"},{"groupId":"OG002","value":"-0.28","spread":"0.76"},{"groupId":"OG003","value":"-0.42","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.75"},{"groupId":"OG001","value":"-0.28","spread":"0.72"},{"groupId":"OG002","value":"-0.32","spread":"0.75"},{"groupId":"OG003","value":"-0.34","spread":"0.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"0.68"},{"groupId":"OG001","value":"-0.28","spread":"0.64"},{"groupId":"OG002","value":"-0.36","spread":"0.72"},{"groupId":"OG003","value":"-0.41","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"0.66"},{"groupId":"OG001","value":"-0.27","spread":"0.64"},{"groupId":"OG002","value":"-0.34","spread":"0.75"},{"groupId":"OG003","value":"-0.39","spread":"0.78"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Participant's Self-Assessment of Dyspareunia (Pain Associated With Sexual Activity) to Weeks 2, 4, 8, 12 and Week 12/Final Visit","description":"Participant's self-assessment of symptoms of VVA (dyspareunia) was scored according to a 4-point scale where: 0= none, 1= mild, 2= moderate, or 3= severe. The negative change from Baseline indicates improvement. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.29","spread":"0.93"},{"groupId":"OG001","value":"2.23","spread":"0.88"},{"groupId":"OG002","value":"2.29","spread":"0.85"},{"groupId":"OG003","value":"2.38","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"1.06"},{"groupId":"OG001","value":"-0.78","spread":"1.07"},{"groupId":"OG002","value":"-0.86","spread":"1.06"},{"groupId":"OG003","value":"-0.67","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.04","spread":"1.06"},{"groupId":"OG001","value":"-1.03","spread":"0.90"},{"groupId":"OG002","value":"-1.06","spread":"1.03"},{"groupId":"OG003","value":"-0.78","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"1.01"},{"groupId":"OG001","value":"-1.04","spread":"0.96"},{"groupId":"OG002","value":"-1.36","spread":"0.97"},{"groupId":"OG003","value":"-1.07","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"1.09"},{"groupId":"OG001","value":"-1.06","spread":"0.96"},{"groupId":"OG002","value":"-1.39","spread":"1.01"},{"groupId":"OG003","value":"-1.09","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"1.07"},{"groupId":"OG001","value":"-1.03","spread":"1.00"},{"groupId":"OG002","value":"-1.35","spread":"1.02"},{"groupId":"OG003","value":"-1.06","spread":"1.07"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Vaginal Bleeding Associated With Sexual Activity as Per Participant's Self-Assessment to Weeks 2, 4, 8, 12 and Week 12/Final Visit","description":"Vaginal bleeding associated with sexual activity was assessed by participants as either \"present\" or \"absent\". Percentage of participants with assessment \"present\" are reported. Week 12/Final Visit is defined as the last available postbaseline assessment up to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.81","spread":null},{"groupId":"OG001","value":"17.89","spread":null},{"groupId":"OG002","value":"17.75","spread":null},{"groupId":"OG003","value":"24.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.55","spread":null},{"groupId":"OG001","value":"7.32","spread":null},{"groupId":"OG002","value":"6.11","spread":null},{"groupId":"OG003","value":"9.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.29","spread":null},{"groupId":"OG001","value":"6.50","spread":null},{"groupId":"OG002","value":"2.64","spread":null},{"groupId":"OG003","value":"5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.61","spread":null},{"groupId":"OG001","value":"4.96","spread":null},{"groupId":"OG002","value":"2.74","spread":null},{"groupId":"OG003","value":"6.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.94","spread":null},{"groupId":"OG001","value":"5.04","spread":null},{"groupId":"OG002","value":"3.35","spread":null},{"groupId":"OG003","value":"6.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.44","spread":null},{"groupId":"OG001","value":"4.88","spread":null},{"groupId":"OG002","value":"3.03","spread":null},{"groupId":"OG003","value":"5.79","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Vaginal pH to Week 12","description":"Vaginal pH was obtained at final visit of the study. The pH was a numeric value from a scale of 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.51","spread":"0.96"},{"groupId":"OG001","value":"6.49","spread":"0.86"},{"groupId":"OG002","value":"6.40","spread":"0.93"},{"groupId":"OG003","value":"6.40","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.10","spread":"1.15"},{"groupId":"OG001","value":"-0.34","spread":"0.89"},{"groupId":"OG002","value":"-1.01","spread":"1.06"},{"groupId":"OG003","value":"-0.47","spread":"0.87"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Percentage of Vaginal Superficial Cells to Week 12","description":"Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"3.76"},{"groupId":"OG001","value":"0.66","spread":"1.62"},{"groupId":"OG002","value":"0.79","spread":"1.63"},{"groupId":"OG003","value":"0.66","spread":"1.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.66","spread":"14.51"},{"groupId":"OG001","value":"3.17","spread":"7.02"},{"groupId":"OG002","value":"17.66","spread":"19.37"},{"groupId":"OG003","value":"3.36","spread":"10.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Percentage of Vaginal Parabasal Cells to Week 12","description":"Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.36","spread":"43.46"},{"groupId":"OG001","value":"47.78","spread":"44.51"},{"groupId":"OG002","value":"42.56","spread":"41.03"},{"groupId":"OG003","value":"45.24","spread":"42.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.3","spread":"42.90"},{"groupId":"OG001","value":"-8.08","spread":"29.90"},{"groupId":"OG002","value":"-39.5","spread":"39.46"},{"groupId":"OG003","value":"-14.9","spread":"31.93"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":238},"commonTop":["Vulvovaginal mycotic infection","Urinary tract infection","Vaginal discharge","Upper respiratory tract infection","Nasopharyngitis"]}}}